{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:02:14Z","timestamp":1756382534186},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herzschr Elektrophys"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00399-021-00755-6","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T15:03:30Z","timestamp":1619017410000},"page":"199-206","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pregnancy in catecholaminergic polymorphic ventricular tachycardia: therapeutic optimization and multidisciplinary care are key to success"],"prefix":"10.1007","volume":"32","author":[{"given":"Thomas M.","family":"Roston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmine","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew D.","family":"Krahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,21]]},"reference":[{"issue":"5","key":"755_CR1","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1161\/01.CIR.91.5.1512","volume":"91","author":"A Leenhardt","year":"1995","unstructured":"Leenhardt\u00a0A, Lucet\u00a0V, Denjoy\u00a0I, Grau\u00a0F, Ngoc\u00a0DD, Coumel\u00a0P (1995) Catecholaminergic polymorphic ventricular tachycardia in children. A 7\u2011year follow-up of 21\u00a0patients. Circulation 91(5):1512\u20131519","journal-title":"Circulation"},{"issue":"12","key":"755_CR2","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.hrthm.2013.05.014","volume":"10","author":"SG Priori","year":"2013","unstructured":"Priori\u00a0SG (2013) HRS\/EHRA\/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm 10(12):1932\u20131963","journal-title":"Heart Rhythm"},{"issue":"7","key":"755_CR3","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1161\/CIRCRESAHA.110.226845","volume":"108","author":"SG Priori","year":"2011","unstructured":"Priori\u00a0SG, Chen\u00a0SR (2011) Inherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesis. Circ Res 108(7):871\u2013883","journal-title":"Circ Res"},{"issue":"3","key":"755_CR4","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/europace\/euw389","volume":"20","author":"TM Roston","year":"2018","unstructured":"Roston\u00a0TM, Yuchi\u00a0Z, Kannankeril\u00a0PJ et\u00a0al (2018) The clinical and genetic spectrum of catecholaminergic polymorphic ventricular tachycardia: findings from an international multicentre registry. Europace 20(3):541\u2013547","journal-title":"Europace"},{"issue":"7","key":"755_CR5","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1253\/circj.CJ-12-1460","volume":"77","author":"M Kawamura","year":"2013","unstructured":"Kawamura\u00a0M, Ohno\u00a0S, Naiki\u00a0N et\u00a0al (2013) Genetic background of catecholaminergic polymorphic ventricular tachycardia in Japan. Circ\u00a0J 77(7):1705\u20131713","journal-title":"Circ J"},{"issue":"4","key":"755_CR6","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1161\/CIRCEP.112.970517","volume":"5","author":"C van der Werf","year":"2012","unstructured":"van der Werf\u00a0C, Nederend\u00a0I, Hofman\u00a0N et al (2012) Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives. Circ Arrhythm Electrophysiol 5(4):748\u2013756","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"6","key":"755_CR7","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1086\/324565","volume":"69","author":"H Lahat","year":"2001","unstructured":"Lahat\u00a0H, Pras\u00a0E, Olender\u00a0T et al (2001) A missense mutation in a\u00a0highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 69(6):1378\u20131384","journal-title":"Am J Hum Genet"},{"issue":"2","key":"755_CR8","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1161\/01.CIR.103.2.196","volume":"103","author":"SG Priori","year":"2001","unstructured":"Priori\u00a0SG, Napolitano\u00a0C, Tiso\u00a0N et\u00a0al (2001) Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 103(2):196\u2013200","journal-title":"Circulation"},{"issue":"11","key":"755_CR9","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/jmg.2004.028993","volume":"42","author":"AV Postma","year":"2005","unstructured":"Postma\u00a0AV, Denjoy\u00a0I, Kamblock\u00a0J et\u00a0al (2005) Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. J\u00a0Med Genet 42(11):863\u2013870","journal-title":"J Med Genet"},{"issue":"22","key":"755_CR10","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/j.jacc.2011.01.026","volume":"57","author":"C van der Werf","year":"2011","unstructured":"van der Werf\u00a0C, Kannankeril\u00a0PJ, Sacher\u00a0F et al (2011) Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J\u00a0Am Coll Cardiol 57(22):2244\u20132254","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"755_CR11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/HCO.0000000000000360","volume":"32","author":"TM Roston","year":"2017","unstructured":"Roston\u00a0TM, Van Petegem\u00a0F, Sanatani\u00a0S (2017) Catecholaminergic polymorphic ventricular tachycardia: a\u00a0model for genotype-specific therapy. Curr Opin Cardiol 32(1):78\u201385","journal-title":"Curr Opin Cardiol"},{"issue":"25","key":"755_CR12","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1161\/CIRCULATIONAHA.115.015731","volume":"131","author":"GM De Ferrari","year":"2015","unstructured":"De Ferrari\u00a0GM, Dusi\u00a0V, Spazzolini\u00a0C et\u00a0al (2015) Clinical management of catecholaminergic polymorphic ventricular tachycardia: the role of left cardiac sympathetic Denervation. Circulation 131(25):2185\u20132193","journal-title":"Circulation"},{"issue":"35","key":"755_CR13","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1093\/eurheartj\/ehz309","volume":"40","author":"C van der Werf","year":"2019","unstructured":"van der Werf C, Lieve KV, Bos JM et al (2019) Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest. Eur Heart\u00a0J 40(35):2953\u20132961. https:\/\/doi.org\/10.1093\/eurheartj\/ehz309","journal-title":"Eur Heart\u00a0J"},{"issue":"12","key":"755_CR14","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/j.hrthm.2018.06.046","volume":"15","author":"TM Roston","year":"2018","unstructured":"Roston TM, Jones K, Hawkins NM et\u00a0al (2018) Implantable cardioverter defibrillator use in catecholaminergic polymorphic ventricular tachycardia: a systematic review. Heart Rhythm 15(12):1791\u20131799. https:\/\/doi.org\/10.1016\/j.hrthm.2018.06.046","journal-title":"Heart Rhythm"},{"issue":"18","key":"755_CR15","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1161\/CIRCULATIONAHA.108.829267","volume":"119","author":"M Hayashi","year":"2009","unstructured":"Hayashi\u00a0M, Denjoy\u00a0I, Extramiana\u00a0F et\u00a0al (2009) Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation 119(18):2426\u20132434","journal-title":"Circulation"},{"issue":"7","key":"755_CR16","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.hrthm.2015.03.033","volume":"12","author":"F Wanguemert","year":"2015","unstructured":"Wanguemert\u00a0F, Bosch Calero\u00a0C, Perez\u00a0C et\u00a0al (2015) Clinical and molecular characterization of a\u00a0cardiac ryanodine receptor founder mutation causing catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 12(7):1636\u20131643","journal-title":"Heart Rhythm"},{"issue":"3","key":"755_CR17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jacep.2018.10.019","volume":"5","author":"CC Cheung","year":"2019","unstructured":"Cheung\u00a0CC, Lieve\u00a0KV, Roston\u00a0TM et\u00a0al (2019) Pregnancy in Catecholaminergic polymorphic ventricular tachycardia. JACC Clin Electrophysiol 5(3):387\u2013394","journal-title":"JACC Clin Electrophysiol"},{"issue":"34","key":"755_CR18","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1093\/eurheartj\/ehy340","volume":"39","author":"V Regitz-Zagrosek","year":"2018","unstructured":"Regitz-Zagrosek\u00a0V, Roos-Hesselink\u00a0JW, Bauersachs\u00a0J et al (2018) 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart\u00a0J 39(34):3165\u20133241","journal-title":"Eur Heart J"},{"issue":"2","key":"755_CR19","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.hrthm.2019.08.004","volume":"17","author":"TM Roston","year":"2020","unstructured":"Roston\u00a0TM, van der Werf\u00a0C, Cheung\u00a0CC et\u00a0al (2020) Caring for the pregnant woman with an inherited arrhythmia syndrome. Heart Rhythm 17(2):341\u2013348","journal-title":"Heart Rhythm"},{"issue":"3","key":"755_CR20","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1161\/CIRCEP.114.002217","volume":"8","author":"TM Roston","year":"2015","unstructured":"Roston\u00a0TM, Vinocur\u00a0JM, Maginot\u00a0KR et\u00a0al (2015) Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry. Circ Arrhythm Electrophysiol 8(3):633\u2013642","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"1","key":"755_CR21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1161\/01.CIR.0000020013.73106.D8","volume":"106","author":"SG Priori","year":"2002","unstructured":"Priori\u00a0SG, Napolitano\u00a0C, Memmi\u00a0M et\u00a0al (2002) Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 106(1):69\u201374","journal-title":"Circulation"},{"issue":"9","key":"755_CR22","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/europace\/eus031","volume":"14","author":"M Hayashi","year":"2012","unstructured":"Hayashi\u00a0M, Denjoy\u00a0I, Hayashi\u00a0M et\u00a0al (2012) The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands. Europace 14(9):1344\u20131351","journal-title":"Europace"},{"issue":"5","key":"755_CR23","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1161\/CIRCGENETICS.113.000118","volume":"6","author":"J Jabbari","year":"2013","unstructured":"Jabbari\u00a0J, Jabbari\u00a0R, Nielsen\u00a0MW et\u00a0al (2013) New exome data question the pathogenicity of genetic variants previously associated with catecholaminergic polymorphic ventricular tachycardia. Circ Cardiovasc Genet 6(5):481\u2013489","journal-title":"Circ Cardiovasc Genet"},{"issue":"5","key":"755_CR24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards\u00a0S, Aziz\u00a0N, Bale\u00a0S et\u00a0al (2015) Standards and guidelines for the interpretation of sequence variants: a\u00a0joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405\u2013424","journal-title":"Genet Med"},{"issue":"5","key":"755_CR25","doi-asserted-by":"crossref","first-page":"e002510","DOI":"10.1161\/CIRCGEN.119.002510","volume":"12","author":"JR Giudicessi","year":"2019","unstructured":"Giudicessi\u00a0JR, Lieve\u00a0KVV, Rohatgi\u00a0RK et al (2019) Assessment and validation of a\u00a0phenotype-enhanced variant classification framework to promote or demote RYR2 Missense variants of uncertain significance. Circ Genom Precis Med 12(5):e2510","journal-title":"Circ Genom Precis Med"},{"issue":"2","key":"755_CR26","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.hrthm.2015.09.029","volume":"13","author":"IS Leren","year":"2016","unstructured":"Leren\u00a0IS, Saberniak\u00a0J, Majid\u00a0E, Haland\u00a0TF, Edvardsen\u00a0T, Haugaa\u00a0KH (2016) Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with beta1-selective beta-blockers in patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 13(2):433\u2013440","journal-title":"Heart Rhythm"},{"issue":"1","key":"755_CR27","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.hrthm.2016.09.012","volume":"14","author":"MJ Ackerman","year":"2017","unstructured":"Ackerman\u00a0MJ, Priori\u00a0SG, Dubin\u00a0AM et al (2017) Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent? Heart Rhythm 14(1):e41\u2013e44","journal-title":"Heart Rhythm"},{"issue":"2","key":"755_CR28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/europace\/eur277","volume":"14","author":"C van der Werf","year":"2012","unstructured":"van der Werf\u00a0C, Zwinderman\u00a0AH, Wilde\u00a0AA (2012) Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments. Europace 14(2):175\u2013183","journal-title":"Europace"},{"key":"755_CR29","doi-asserted-by":"publisher","first-page":"ehaa946.0755","DOI":"10.1093\/ehjci\/ehaa946.0755","volume":"Supplement_2","author":"P Peltenburg","year":"2020","unstructured":"Peltenburg P, Lieve KVV, Van Der Werf C et\u00a0al (2020) Atenolol is not effective in reducing ventricular arrhythmia severity on exercise stress test in patients with catecholaminergic polymorphic ventricular tachycardia. Eur Heart\u00a0J 41(Supplement_2):ehaa946.0755. https:\/\/doi.org\/10.1093\/ehjci\/ehaa946.0755","journal-title":"Eur Heart\u00a0J"},{"issue":"1","key":"755_CR30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40842-018-0054-7","volume":"4","author":"CT Nguyen","year":"2018","unstructured":"Nguyen\u00a0CT, Sasso\u00a0EB, Barton\u00a0L, Mestman\u00a0JH (2018) Graves\u2019 hyperthyroidism in pregnancy: a\u00a0clinical review. Clin Diabetes Endocrinol 4(1):4","journal-title":"Clin Diabetes Endocrinol"},{"issue":"3","key":"755_CR31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1365-2125.1981.tb01232.x","volume":"12","author":"RG Devlin","year":"1981","unstructured":"Devlin\u00a0RG, Duchin\u00a0KL, Fleiss\u00a0PM (1981) Nadolol in human serum and breast milk. Br J Clin Pharmacol 12(3):393\u2013396","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"755_CR32","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1001\/jamacardio.2017.1320","volume":"2","author":"PJ Kannankeril","year":"2017","unstructured":"Kannankeril\u00a0PJ, Moore\u00a0JP, Cerrone\u00a0M et\u00a0al (2017) Efficacy of Flecainide in the treatment of Catecholaminergic polymorphic ventricular tachycardia: a randomized clinical trial. JAMA Cardiol 2(7):759\u2013766","journal-title":"JAMA Cardiol"},{"issue":"2","key":"755_CR33","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.hrthm.2015.09.027","volume":"13","author":"GJ Padfield","year":"2016","unstructured":"Padfield\u00a0GJ, AlAhmari\u00a0L, Lieve\u00a0KV et al (2016) Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of beta-blockade. Heart Rhythm 13(2):609\u2013613","journal-title":"Heart Rhythm"},{"issue":"2","key":"755_CR34","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/1753495X18808118","volume":"12","author":"I Malham\u00e9","year":"2019","unstructured":"Malham\u00e9\u00a0I, Gandhi\u00a0C, Tarabulsi\u00a0G et\u00a0al (2019) Maternal monitoring and safety considerations during antiarrhythmic treatment for fetal supraventricular tachycardia. Obstet Med 12(2):66\u201375","journal-title":"Obstet Med"},{"issue":"6","key":"755_CR35","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1053\/euhj.2000.2130","volume":"22","author":"HL Tan","year":"2001","unstructured":"Tan\u00a0HL, Lie\u00a0KI (2001) Treatment of tachyarrhythmias during pregnancy and lactation. Eur Heart\u00a0J 22(6):458\u2013464","journal-title":"Eur Heart J"},{"issue":"3","key":"755_CR36","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1161\/CIRCEP.113.000170","volume":"6","author":"CY Miyake","year":"2013","unstructured":"Miyake\u00a0CY, Webster\u00a0G, Czosek\u00a0RJ et\u00a0al (2013) Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: success depends on substrate. Circ Arrhythm Electrophysiol 6(3):579\u2013587","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"1","key":"755_CR37","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.hrthm.2013.10.027","volume":"11","author":"F Roses-Noguer","year":"2014","unstructured":"Roses-Noguer\u00a0F, Jarman\u00a0JW, Clague\u00a0JR, Till\u00a0J (2014) Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 11(1):58\u201366","journal-title":"Heart Rhythm"},{"issue":"6","key":"755_CR38","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nrcardio.2014.19","volume":"11","author":"PJ Schwartz","year":"2014","unstructured":"Schwartz\u00a0PJ (2014) Cardiac sympathetic denervation to prevent life-threatening arrhythmias. Nat Rev Cardiol 11(6):346\u2013353","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"755_CR39","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1213\/XAA.0000000000000858","volume":"12","author":"L Scalercio","year":"2019","unstructured":"Scalercio\u00a0L, Vitter\u00a0J, Elliott\u00a0CE (2019) Placement of a\u00a0continuous stellate ganglion block for treatment of refractory ventricular fibrillation in the setting of known Prinzmetal angina during pregnancy: a case report. A\u00a0A Pract 12(4):106\u2013108","journal-title":"A A Pract"},{"issue":"4","key":"755_CR40","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/ccr3.366","volume":"4","author":"A Ahmed","year":"2016","unstructured":"Ahmed\u00a0A, Phillips\u00a0JR (2016) Teenage pregnancy with catecholaminergic polymorphic ventricular tachycardia and documented ICD discharges. Clin Case Rep 4(4):361\u2013365","journal-title":"Clin Case Rep"},{"issue":"7","key":"755_CR41","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1007\/s00246-015-1232-3","volume":"36","author":"KP Friday","year":"2015","unstructured":"Friday\u00a0KP, Moak\u00a0JP, Fries\u00a0MH, Iqbal\u00a0SN (2015) Catecholaminergic ventricular tachycardia, pregnancy and teenager: are they compatible? Pediatr Cardiol 36(7):1542\u20131547","journal-title":"Pediatr Cardiol"},{"issue":"5","key":"755_CR42","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/jcph.631","volume":"56","author":"RJ Ryu","year":"2016","unstructured":"Ryu\u00a0RJ, Eyal\u00a0S, Easterling\u00a0TR et\u00a0al (2016) Pharmacokinetics of metoprolol during pregnancy and lactation. J\u00a0Clin Pharmacol 56(5):581\u2013589","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"755_CR43","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.107.728840","volume":"118","author":"CB Overgaard","year":"2008","unstructured":"Overgaard\u00a0CB, D\u017eav\u00edk\u00a0V (2008) Inotropes and Vasopressors. Circulation 118(10):1047\u20131056","journal-title":"Circulation"},{"issue":"4","key":"755_CR44","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.cjca.2019.01.013","volume":"35","author":"TM Roston","year":"2019","unstructured":"Roston\u00a0TM, Chua\u00a0D, Lum\u00a0E, Krahn\u00a0AD (2019) Switching Between beta-Blockers: An Empiric Tool for the Cardiovascular Practitioner. Can J Cardiol 35(4):539\u2013543","journal-title":"Can J Cardiol"}],"container-title":["Herzschrittmachertherapie + Elektrophysiologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00399-021-00755-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00399-021-00755-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00399-021-00755-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T12:07:38Z","timestamp":1622462858000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00399-021-00755-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,21]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["755"],"URL":"https:\/\/doi.org\/10.1007\/s00399-021-00755-6","relation":{},"ISSN":["0938-7412","1435-1544"],"issn-type":[{"value":"0938-7412","type":"print"},{"value":"1435-1544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,21]]},"assertion":[{"value":"7 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T.M.\u00a0Roston, J.\u00a0Grewal, and A.D.\u00a0Krahn declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}